Physician profile
Gary Nelson
NPI 1093773574
$4,697.85
in general payments reported to CMS, 2019-2025
45 companies · $452 in 2025
The $452 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $446 · 2021: $1,009 · 2022: $811 · 2023: $572 · 2024: $417 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.33 | 2019-2023 | |
| Avion Pharmaceuticals | $328.01 | 2020-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $283.18 | 2019-2025 | |
| Astellas Pharma US INC | $279.30 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $275.23 | 2019-2024 | |
| Mylan Pharmaceuticals INC. | $227.71 | 2020-2022 | |
| Novo Nordisk INC | $168.83 | 2020-2023 | Wegovy |
| Hologic Sales and Service, LLC | $165.74 | 2019-2025 | Coolseal Generator, Aptima |
| Sumitomo Pharma America, INC. | $161.55 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $155.05 | 2019-2022 | |
| Myovant Sciences INC. | $149.89 | 2021-2022 | |
| Roche Diagnostics Corporation | $149.66 | 2019-2021 | |
| Coopersurgical, INC. | $121.62 | 2019-2023 | Mara Console, Paragard T 380a |
| Mayne Pharma Commercial LLC | $120.91 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.73 | 2019-2025 | Trintellix |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $105.71 | 2023-2024 | Accrufer |
| Organon LLC | $105.10 | 2022-2025 | Nexplanon |
| Millicent US INC | $92.29 | 2019-2025 | Intrarosa, Femring |
| Meditrina | $83.15 | 2022-2023 | |
| Evofem Biosciences, INC. | $79.75 | 2021-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $79.26 | 2019-2025 | Slynd |
| Duchesnay USA Incorporated | $70.71 | 2019 | |
| Boston Scientific Corporation | $68.59 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $65.96 | 2020-2022 | |
| Allergan, INC. | $47.45 | 2019 | |
| Channel Medsystems, INC. | $46.69 | 2024-2025 | |
| Axsome Therapeutics, INC. | $45.77 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $42.98 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $39.26 | 2019 | |
| Sage Therapeutics, LLC | $33.92 | 2024-2025 | Zurzuvae |
| Biom'Up France Sas | $32.35 | 2021 | |
| Exact Sciences Corporation | $31.41 | 2025 | The Cologuard Plus Collection Kit |
| Vivus LLC | $29.41 | 2019-2020 | |
| Lsi Solutions INC | $27.01 | 2021 | |
| Lilly USA, LLC | $17.40 | 2024 | Zepbound |
| Vertex Pharmaceuticals Incorporated | $17.25 | 2025 | |
| Sanofi Pasteur INC. | $15.87 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.08 | 2019 | |
| Covidien Lp | $14.66 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.65 | 2019 | |
| Agile Therapeutics, INC. | $13.97 | 2024 | Twirla |
| Shire North American Group INC | $13.40 | 2019 | |
| Coloplast Corp | $12.76 | 2021 | |
| Amgen INC. | $12.59 | 2019 | |
| Lupin INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.